Vaxxinity, Inc.

Vaxxinity, Inc. is a biotechnology company that aims to democratize health by bringing the efficiency of vaccines to chronic diseases. The company uses its synthetic peptide vaccine platform to harness the immune system and convert the body into its own 'drug factory', stimulating the production of antibodies with a therapeutic effect. Its current pipeline consists of five chronic disease candidates from early to late-stage development across multiple therapeutic areas including Alzheimer’s, Parkinson’s, migraine and hypercholesterolemia as well as a candidate for COVID-19 prevention. The company was founded by Louis G. Reese IV and Mei Mei Hu in 2014 and is headquartered in Dallas, TX.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vaxxinity, Inc. is a biotechnology company that aims to democratize health by bringing the efficiency of vaccines to chronic diseases. The company uses its synthetic peptide vaccine platform to harness the immune system and convert the body into its own 'drug factory', stimulating the production of antibodies with a therapeutic effect. Its current pipeline consists of five chronic disease candidates from early to late-stage development across multiple therapeutic areas including Alzheimer’s, Parkinson’s, migraine and hypercholesterolemia as well as a candidate for COVID-19 prevention. The company was founded by Louis G. Reese IV and Mei Mei Hu in 2014 and is headquartered in Exploration Park, FL.

CAPE CANAVERAL, Fla., March 21, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, announced today that it has joined TransCelerate BioPharma, Inc. (TransCelerate) as the first emerging biotechnology organization of the trailblazing consortium that is accelerating and simplifying the research and development of innovative new therapies.

Vaxxinity Joins TransCelerate Research and Development Consortium

CAPE CANAVERAL, Fla., March 20, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that the first subjects have been dosed in a randomized, double-blind, placebo-controlled Phase 1 clinical trial of VXX-401, an investigational vaccine designed to lower low-density lipoprotein (LDL) cholesterol, a known factor contributing to heart disease, by targeting proprotein convertase subtilisin/kexin type 9 serine protease (PCSK9). Heart disease remains the leading cause of death globally, claiming over 18 million lives per year, despite the existence of approved treatments that lower LDL.

Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat Hypercholesterolemia

Vaxxinity to present new preclinical data on anti-tau Alzheimer's vaccine candidate VXX-301 at AD/PD International Conference Vaxxinity to present new preclinical data on anti-tau Alzheimer's vaccine candidate VXX-301 at AD/PD International Conference

Vaxxinity to Present at Upcoming March Scientific and Medical Conferences

NEW YORK--(BUSINESS WIRE)-- #IR--ICR, a leading strategic communications and advisory firm, is pleased to announce that Mei Mei Hu, Chief Executive Officer and Co-Founder, Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, recently appeared on Episode 64 of ICR's “Welcome to the Arena” podcast. Welcome to the Arena is hosted by Tom Ryan, Co-Founder & CEO of ICR.

ICR Hosts Vaxxinity CEO Mei Mei Hu on the Welcome to the Arena Podcast

AlTi Global, Inc.

BigBear.ai Holdings

Dragonfly Energy Holdings Corp

Enovix Corporation

Fate Therapeutics

Faraday Future Intelligent Electric

MotorSport Games

FiscalNote Holdings Inc

Theseus Pharmaceuticals

Small-cap stocks are expected to perform well this year. The Bank of America Securities, in fact, is asking investors to consider small caps this year to hedge against a declining market.

The 5 Best and Worst Performing Small-Cap Stocks in January 2023

Appointment of new directors bring diversity, balance and relevant industry expertise to Vaxxinity

Vaxxinity Announces Board Appointments and Establishes New Headquarters in Florida

Investors are hoping the company's COVID-19 vaccine will turn the company from a clinical-stage biotech to a commercial one.

Why Shares of Vaxxinity Jumped This Week

We may not be at the end credits for COVID-19 virus. Shares of Vaxxinity, Inc., like most biotechs, have plummeted over the past year due to unprecedented market headwinds, both macroeconomic and geopolitical.

Vaxxinity: Potential Strong Upsides Ahead

Vaxxinity's next-generation COVID-19 booster candidate UB-612 achieves primary and key secondary immunogenicity endpoints in a pivotal head-to-head heterologous booster trial against three authorized vaccine platforms: mRNA (Pfizer-BioNTech's BNT162b2), adenovirus vector (AstraZeneca's ChAdOx1-S), and inactivated virus (Sinopharm's BIBP)

Vaxxinity Announces Positive Topline Pivotal Phase 3 COVID-19 Booster Data for UB-612

Positive news regarding a different company's Alzheimer's treatment may have helped Vaxxinity.

Why Shares of Vaxxinity Soared This Week

Phase 1 Part B End-of-Treatment Data Show UB-312 is Well Tolerated and Immunogenic in Parkinson's Disease Patients

Vaxxinity Reports Third Quarter 2022 Financial Results and Provides Corporate Update

DALLAS, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu, Chief Executive Officer of Vaxxinity, will present and participate in meetings at the following investor conferences in November:

Vaxxinity to Present at Upcoming Investor Conferences in November

DALLAS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that the first subjects have been dosed in a Phase 1 clinical trial of UB-313, a vaccine targeting calcitonin gene-related peptide (CGRP), for the preventive treatment of migraine.

Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of UB-313 for Preventive Treatment of Migraine

• UB-612 Phase 3 COVID-19 Heterologous Boost Trial on Track for Topline Readout in Fourth Quarter of 2022

Vaxxinity Reports Second Quarter 2022 Financial Results and Provides Corporate Updates

DALLAS, May 09, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the first quarter ended March 31, 2022.

Vaxxinity Reports First Quarter 2022 Financial Results and Provides Corporate Updates

VAXX stock gained more than 80% on Friday after Vaxxinity announced it has enrolled patients for the next part of its trials. The post Why Did Vaxxinity (VAXX) Stock Gain 80% Today?

Why Did Vaxxinity (VAXX) Stock Gain 80% Today?

OSLO, Norway and DALLAS, April 06, 2022 (GLOBE NEWSWIRE) -- The Coalition for Epidemic Preparedness Innovations (CEPI) and Vaxxinity, Inc. (Nasdaq: VAXX), a US company pioneering the development of a new class of immunotherapeutic vaccines, today announced that they will co-fund the ongoing global pivotal Phase 3 clinical trial of Vaxxinity's next generation UB-612 COVID-19 vaccine candidate as a heterologous – or ‘mix-and-match' – booster dose. CEPI will provide up to $9.25m in funding.

CEPI to co-fund Vaxxinity's pivotal Phase 3 UB-612 heterologous booster trial to combat SARS-CoV-2 variants

DALLAS, March 24, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2021.

Vaxxinity Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Updates

DALLAS, March 21, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines for chronic diseases, today announced that Peter Powchik, M.D. is joining its Board of Directors and will be retiring as Vaxxinity's Executive Vice President, Research & Development. This transition will be effective March 31, 2022 and will increase the size of the Board to seven.

Vaxxinity Appoints Dr. Peter Powchik to Board of Directors

DALLAS, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced results from studies demonstrating the ability of UB-612, its COVID-19 vaccine candidate, to elicit a broad immune response against multiple variants of concern, and specifically more than three-times higher titers of neutralizing antibodies against the Omicron variant of SARS-CoV-2 than an approved mRNA vaccine with boosters.

Vaxxinity's COVID-19 Vaccine Candidate UB-612 Produces High Levels of Neutralizing Antibodies Against Omicron and Other Variants of Concern

Vaxxinity (VAXX) starts dosing patients in part B of a phase I study on its investigational Parkinson's disease vaccine candidate.

Vaxxinity (VAXX) Starts Dosing in Parkinson's Disease Study

The stock price of Vaxxinity Inc (NASDAQ: VAXX) increased by 29.67% today. This is why it happened.

Vaxxinity Stock (VAXX): Why The Price Went Up Today

DALLAS, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that the first patient with Parkinson's disease (PD) has been dosed with UB-312 in Part B of a double-blinded, placebo-controlled Phase 1 clinical trial, following completion of Part A of the Phase 1 trial in healthy volunteers.

Vaxxinity Announces First Parkinson's Disease Patient Dosed in Part B of Phase 1 Clinical Trial of UB-312

DALLAS, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the third quarter ended September 30, 2021.

Vaxxinity Reports Third Quarter 2021 Financial Results and Provides Corporate Updates

Investors have trouble valuing the biotech's IPO.

News for Vaxxinity, Inc. Stock (VAXX)